4/11/2012

The FDA told Vivus it won't rule on weight-loss pill Qnexa until July 17 because the agency needs extra time to look at the drugmaker's risk evaluation and mitigation strategy. In February, an advisory panel decided that Qnexa's benefits outweigh the risks.

Full Story:
Reuters

Related Summaries